Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK Study of Psilocin Mucate (L-130) in Healthy Subjects
NCT06035900Phase 1Completed
- Sponsor
- Lobe Sciences Ltd.
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocin mucate in Cluster Headache (CH), sponsored by Lobe Sciences Ltd. Primary endpoint: Determination of adverse events at 28 days. Started Jun 2023; status: completed.
02
Drugs
psilocin mucate
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT06035900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035900.